AVTXAvalo Therapeutics, Inc.

Nasdaq avalotx.com


$ 15.81 $ 0.96 (6.41 %)    

Friday, 26-Apr-2024 15:57:31 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 15.94
$ 15.15
$ 0.00 x 0
$ 15.79 x 200
$ 14.76 - $ 15.81
$ 3.95 - $ 1,130.40
78,226
na
16.48M
$ 0.69
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-29-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-03-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 03-29-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 03-02-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-02-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-08-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-11-2020 12-31-2019 10-K
18 11-14-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-18-2019 12-31-2018 10-K
22 11-13-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-11-2018 03-31-2018 10-Q
25 04-02-2018 12-31-2017 10-K
26 11-07-2017 09-30-2017 10-Q
27 08-14-2017 06-30-2017 10-Q
28 05-09-2017 03-31-2017 10-Q
29 03-14-2017 12-31-2016 10-K
30 11-08-2016 09-30-2016 10-Q
31 08-15-2016 06-30-2016 10-Q
32 05-16-2016 03-31-2016 10-Q
33 03-23-2016 12-31-2015 10-K
34 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 avalo-therapeutics-newly-acquired-ex-eli-lilly-drug-could-stand-out-in-competitive-hidradenitis-suppurativa-market-analyst-upgrades

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades t...

 oppenheimer-upgrades-avalo-therapeutics-to-outperform-announces-35-price-target

Oppenheimer analyst Leland Gershell upgrades Avalo Therapeutics (NASDAQ:AVTX) from Perform to Outperform and announces $35 p...

 why-stryve-foods-shares-are-trading-lower-by-around-25-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.

 why-virtra-shares-are-trading-higher-by-around-20-here-are-20-stocks-moving-premarket

Shares of VirTra, Inc. (NASDAQ: VTSI) rose sharply in today’s pre-market trading after the company reported better-than-expect...

 why-doma-holdings-shares-are-trading-higher-by-around-34-here-are-20-stocks-moving-premarket

Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transa...

 crude-oil-surges-over-2-msc-industrial-shares-fall-after-q2-results

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 15 points on Thursday. The Dow tr...

 why-kodiak-sciences-shares-are-trading-lower-by-around-20-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...

 gold-gains-1-walgreens-narrows-earnings-forecast

U.S. stocks traded slightly higher midway through trading, with the S&P 500 gaining around 0.1% on Thursday. The Dow trade...

 rex-american-resources-reports-upbeat-earnings-joins-avalo-therapeutics-rh-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corpo...

 us-stocks-flat-initial-jobless-claims-fall-to-210000

U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening ...

 micro-cap-avalo-therapeutics-stock-rallies-as-it-snaps-almatabio-for-ex-eli-lilly-drug-for-skin-disorder

Avalo Therapeutics shares are soaring after acquiring AVTX-009, a Phase 2-ready anti-IL-1β mAb. With $185 million in gross proc...

Core News & Articles
Market-Moving News for March 28th
03/28/2024 12:36:38

AVTX: 406% | Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million XLO: 399% | Xilio T...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION